Novartis India (NSE:NOVARTIND) Other Stockholders Equity: ₹8,055 Mil (As of Mar. 2026)


NSE:NOVARTIND Novartis India Ltd NSE:NOVARTIND
62 GF Score
Price ₹1,494.60
GF Value ₹642.38
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis India Other Stockholders Equity?

Novartis India NSE:NOVARTIND +1.93% 62 Other Stockholders Equity is ₹8,055 Mil as of Mar. 2026. GuruFocus rates NSE:NOVARTIND with a GF Score™ of 62/100 and a GF Value™ of ₹642.38 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Novartis India's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹8,055 Mil.

Novartis India's quarterly Other Stockholders Equity declined from Sep. 2025 (₹7,627 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹8,055 Mil).

Novartis India's annual Other Stockholders Equity stayed the same from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹0 Mil) but then increased from Mar. 2025 (₹0 Mil) to Mar. 2026 (₹8,055 Mil).

Novartis India Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Novartis India's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis India Other Stockholders Equity Chart

Novartis India Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -22.20 -0.40 0.00 0.00 8,054.90

Novartis India Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 7,627.30 0.00 8,054.90
NSE:NOVARTIND
62GF Score
Novartis India Ltd NSE:NOVARTIND
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis India Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹8,055 Mil mean?
Novartis India (NSE:NOVARTIND) has a Other Stockholders Equity of ₹8,055 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novartis India and its competitors.
Is Novartis India's Other Stockholders Equity too high?
Novartis India's current Other Stockholders Equity is ₹8,055 Mil. Overall, Novartis India has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Other Stockholders Equity compare to ZTS and UTHR?
Novartis India's Other Stockholders Equity of ₹8,055 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Novartis India and its competitors. Novartis India's current Other Stockholders Equity is ₹8,055 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (NSE:NOVARTIND) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹642.38, compared to a current price of ₹1,494.60 — trading 132.7% above its estimated fair value. The current Other Stockholders Equity is ₹8,055 Mil. Novartis India's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Novartis India (NSE:NOVARTIND), the current Other Stockholders Equity is ₹8,055 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis India (NSE:NOVARTIND) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis India stock appears to be overvalued. The current stock price of ₹1,494.60 is trading 132.7% above its estimated GF Value™ of ₹642.38. GuruFocus considers Novartis India to be Significantly Overvalued.

Key valuation signals for NSE:NOVARTIND:

  • Other Stockholders Equity: ₹8,055 Mil
  • GF Value™: ₹642.38 vs. price of ₹1,494.60 (132.7% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the NSE:NOVARTIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis India Business Description

Other Exchanges 500672:India
Address Inspire BKC, Part of 601 & 701, Bandra Kurla Complex, Bandra (East), Mumbai, MH, IND, 400 051
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
62GF Score

Get the complete analysis for NSE:NOVARTIND

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,494.60
Price
₹642.38
GF Value